Showing 241 - 250 of 319
Persistent link: https://www.econbiz.de/10012082311
Persistent link: https://www.econbiz.de/10012082355
Persistent link: https://www.econbiz.de/10012082362
Persistent link: https://www.econbiz.de/10012082444
Persistent link: https://www.econbiz.de/10013122770
This paper builds on the methods of local instrumental variables developed by Heckman and Vytlacil (1999, 2001, 2005) to estimate person-centered treatment (PeT) effects that are conditioned on the person's observed characteristics and averaged over the potential conditional distribution of...
Persistent link: https://www.econbiz.de/10013106654
Public subsidization of technology assessments in general, and Comparative Effectiveness Research (CER) in particular, has received considerable attention as a tool to simultaneously improve patient health and lower the cost of health care. However, little conceptual and empirical understanding...
Persistent link: https://www.econbiz.de/10013092707
The United States aspires to use information from comparative effectiveness research (CER) to reduce waste and contain costs without instituting a formal rationing mechanism or compromising patient or physician autonomy with regard to treatment choices. With such ambitious goals, traditional...
Persistent link: https://www.econbiz.de/10013068360
Under the assumption of no unmeasured confounders, a large literature exists on methods that can be used to estimating average treatment effects (ATE) from observational data and that spans regression models, propensity score adjustments using stratification, weighting or regression and even the...
Persistent link: https://www.econbiz.de/10012759214
Features of Part D gave rise to broad concern that the drug benefit would negatively impact prescription utilization among the six million dual eligible beneficiaries, either during the transition from state Medicaid to Part D coverage, or in the long-run. At the same time, Part D contained...
Persistent link: https://www.econbiz.de/10012769646